Clinical Trial

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-10-30; most recent amendment 2026-07-02.
Trial Details
NCT Number NCT07223125
Lead Sponsor Janssen Research & Development, LLC
Conditions Advanced-stage Solid Tumors
Enrollment 360 participants
Start Date 2025-10-10
Primary Completion 2026-12-15 (estimated)
Study Completion 2028-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-06